Valentina Rossi: Addressing Inflammation and Immune Mechanisms in Cardiomyopathy Management
Valentina Rossi, Specialist in Cardiology and Internal Medicine at The University Hospital Zurich, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“My first manuscript within my PhD program at the Maastricht University about Immune-Mediated Cardiomyopathies and Their Impact on Long-Term Outcomes has been just published in the European Journal of Heart Failure! Key findings include:
- Higher Risk of Adverse Events: Patients with ID-CMP face a significantly higher risk of major adverse cardiovascular events (MACE), including cardiac mortality, heart failure hospitalization, and life-threatening arrhythmias, compared to non-immune DCM patients.
- Inflammation as a Key Factor: Persistent myocardial inflammation, evidenced by elevated immune cell counts (CD3+, CD45+, CD68+), is linked to worse outcomes, independent of genetic factors or left ventricular ejection fraction (LVEF) recovery.
- Similar LVEF Trajectories: Despite worse outcomes, ID-CMP patients show comparable long-term LVEF recovery to nonID-CMP patients, suggesting factors beyond systolic function drive disease progression.
- Validation Across Cohorts: Findings were confirmed in an external validation cohort, highlighting the need for tailored management and enhanced cardiovascular surveillance for ID-CMP patients.
This study underscores the importance of addressing inflammation and immune mechanisms in cardiomyopathy management.”
Title: Clinical characteristics and outcomes of cardiomyopathies related to immune-mediated diseases
Authors: Valentina A Rossi, Maurits A Sikking, Alessandro Folgheraiter, Carola Pio Loco, Fernando Dominguez, Bastien S C Nihant, Sophie L V M Stroeks, Michiel T H M Henkens, Nerea Mora-Ayestarán, Noemí Ramos-López, Gianfranco Sinagra, Pablo Garcia-Pavia, Frank Ruschitzka, Marco Merlo, Job A J Verdonschot, Stephane R B Heymans
Read the Full Article on European Heart Journal.
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC